Evidence-based treatment for HIV-associated dementia and cognitive impairment: why so little?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. HIV associated epigenetic trends and chronic diseases: insights into the hidden burden of chronic infection.Clinical epigenetics · 2026
   Review
2. In vitro and Ex vivo Neurotoxic Effects of Efavirenz are Greater than Those of Other Common Antiretrovirals.Neurochemical research · 2017
   Article
3. Soluble and cell-associated insulin receptor dysfunction correlates with severity of HAND in HIV-infected women.PloS one · 2012
   Article
4. Early emergence and selection of a SIV-LTR C/EBP site variant in SIV-infected macaques that increases virus infectivity.PloS one · 2012
   Article

Corrections and comments

• Comment on
  Factors in AIDS dementia complex trial design: results and lessons from the abacavir trial.2007

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.